Literature DB >> 6437960

The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.

J W Kesterson, G R Granneman, J M Machinist.   

Abstract

Valproic acid (VPA), its unsaturated metabolites and pent-4-enoate (4-PA) were studied for potential hepatotoxicity in rats. 4-PA, 4-en-VPA and 2,4-dien-VPA were potent inducers of microvesicular steatosis in young rats. Microvesicular steatosis induced by the 4-en-VPA was accompanied by ultrastructural changes characterized by myeloid bodies, lipid vacuoles and mitochondrial abnormalities. Myeloid bodies and lipid vacuoles were seen to a lesser extent in 2,4-dien-VPA and 4-PA-treated rats. VPA failed to induce discernible liver lesions in young rats even at near lethal doses of 700 mg per kg per day. The drug did, however, induce hepatic lipid accumulation in mature rats and in young rats dosed concomitantly with phenobarbital. beta-oxidation inhibition and several other biochemical alterations were observed in rats dosed with VPA, its unsaturated metabolites and 4-PA. It was suggested that beta-oxidation inhibition observed in both VPA and en-metabolite-treated rats occurred by different mechanisms. VPA inhibits by a transient sequestering of CoA while the CoA esters of some en-VPA-metabolites, particularly 4-en-VPA, inhibit specific enzyme(s) in the beta-oxidation sequences.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437960     DOI: 10.1002/hep.1840040609

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.

Authors:  R N Ratnaike; G J Schapel; G Purdie; R H Rischbieth; S Hoffmann
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

Review 3.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

4.  Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats.

Authors:  D Hönack; C Rundfeldt; W Löscher
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

5.  The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.

Authors:  T Kondo; K Otani; T Hirano; S Kaneko; Y Fukushima
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Hepatic injury caused by mianserin.

Authors:  K Otani; S Kaneko; H Tasaki; Y Fukushima
Journal:  BMJ       Date:  1989-08-19

Review 7.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

8.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 9.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.

Authors:  A Haj-Yehia; S Hadad; M Bialer
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.